Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma: Preliminary results from an exploratory prospective clinical study.

被引：0
|
作者：
Dong, Pei [1 ]
Wei, Wensu [1 ]
Jiang, Lijuan [1 ]
Zhang, Zhiling [1 ]
Guo, Shengjie [1 ]
Han, Hui [1 ]
Cai, Xiuyu [1 ]
Zhou, Fangjian [1 ]
机构：
[1] Sun Yat Sen Univ, Dept Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16546
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study
    Dong, Pei
    Wei, Wensu
    Jiang, Lijuan
    Zhang, Zhiling
    Wang, Deling
    Peng, Yulu
    Huang, Tingxuan
    Zhong, Xi
    Guo, Shengjie
    Han, Hui
    Cai, Xiuyu
    Zhou, Fangjian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] An exploratory prospective clinical study on efficacy and safety of anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma
    Dong, P.
    Wei, W.
    Jiang, L.
    Zhang, Z.
    Guo, S.
    Han, H.
    Cai, X.
    Zhou, F.
    EUROPEAN UROLOGY, 2023, 83 : S753 - S753
  • [3] Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
    Laramee, Sophie
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Hansen, Aaron Richard
    Wood, Lori
    Soulieres, Denis
    Canil, Christina M.
    Saleh, Ramy
    Castonguay, Vincent
    Bjarnason, Georg A.
    Basappa, Naveen S.
    Breau, Rodney H.
    Heng, Daniel Yick Chin
    Pouliot, Frederic
    Kapoor, Anil
    Lalani, Aly-Khan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [4] Current evidences in the first-line treatment of metastatic non-clear cell renal cell carcinoma
    Inokuchi, Junichi
    Goto, Shunsuke
    Monji, Keisuke
    Eto, Masatoshi
    ANNALS OF ONCOLOGY, 2023, 34 : S1362 - S1362
  • [5] First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series
    Buti, Sebastiano
    Bersanelli, Melissa
    Massari, Francesco
    De Giorgi, Ugo
    Caffo, Orazio
    Aurilio, Gaetano
    Basso, Umberto
    Carteni, Giacomo
    Caserta, Claudia
    Galli, Luca
    Boccardo, Francesco
    Procopio, Giuseppe
    Facchini, Gaetano
    Fornarini, Giuseppe
    Berruti, Alfredo
    Fea, Elena
    Naglieri, Emanuele
    Petrelli, Fausto
    Iacovelli, Roberto
    Porta, Camillo
    Mosca, Alessandra
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2021, 12 (11): : 1037 - 1046
  • [6] First-line pazopanib in non-clear cell renal carcinoma: The Italian retrospective multicenter PANORAMA study.
    Buti, Sebastiano
    Bersanelli, Melissa
    Maines, Francesca
    Facchini, Gaetano
    Gelsomino, Francesco
    Zustovich, Fable
    Santoni, Matteo
    Verri, Elena
    De Giorgi, Ugo
    Masini, Cristina
    Morelli, Franco
    Vitale, Maria Giuseppa
    Sava, Teodoro
    Prati, Giuseppe
    Librici, Carmelinda
    Fraccon, Anna Paola
    Fornarini, Giuseppe
    Leonardi, Francesco
    Caffo, Orazio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [7] ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma
    Zhang, Hailiang
    Ye, Ding-Wei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
    Graham, Jeffrey
    Wells, John Connor
    Dudani, Shaan
    Gan, Chun L.
    Donskov, Frede
    Lee, Jae-Lyun
    Kollmannsberger, Christian K.
    Meza, Luis
    Beuselinck, Benoit
    Hansen, Aaron
    North, Scott A.
    Bjarnason, Georg A.
    Sayegh, Nicolas
    Kanesvaran, Ravindran
    Wood, Lori A.
    Hotte, Sebastien J.
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Y. C.
    EUROPEAN JOURNAL OF CANCER, 2022, 171 : 124 - 132
  • [9] Anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma: A single-center, single-arm, phase II trial
    Zhang, Hailiang
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC).
    Graham, Jeffrey
    Wells, Connor
    Dudani, Shaan
    Gan, Chun Loo
    Donskov, Frede
    Lee, Jae-Lyun
    Kollmannsberger, Christian K.
    Pal, Sumanta K.
    Beuselinck, Benoit
    Hansen, Aaron Richard
    North, Scott A.
    Bjarnason, Georg A.
    Agarwal, Neeraj
    Kanesvaran, Ravindran
    Wood, Lori
    Hotte, Sebastien J.
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345